Dr. Kaixian Chen (陈凯先), a member of Chinese Academy of Sciences, has recently accepted the invitation to join our organization as a CBA Scientific Advisor.
Dr. Kaixian Chen has committed himself to research in the areas of organic chemistry, medicinal chemistry and drug design for many years. Through theoretical calculation and molecular modeling, his group has developed and improved many methods and techniques for drug design, studied in depth structure-function relationships of many biological macromolecules, structure-activity relationships as well as mechanism of action of a significant number of biologically active small molecules. Focusing on a series of important drug targets, his team has conducted high throughput virtual screenings, lead discovery researches, prediction and design of biological active small molecules. Through these studies, Dr. Chen has promoted the interdisciplinary exchanges and integrations among medicinal chemistry, life sciences, computer science and informatics, achieving a contribution towards innovative drug research in China.
CBA is very honored to have Dr. Chen join us at the 20th Annual Conference of CBA (2015, China). Dr. Chen’s thought-provoking lecture attributes tremendously to the success of this 20th anniversary event of CBA.
Since its founding over 20 years ago, CBA has been serving as a bridge between US and China in the field of bio-med research with the goal of bringing new pharmaceutical agents to commercial development and healthcare market. Among many US-based professional societies and associations, CBA stands out as one of the most active, vibrant and engaging organizations. Dr. Kaixian Chen’s wealth of scientific knowledge and experience in scientific communities will be a great asset to CBA’s future growth and our continued involvement in scientific research and biopharmaceutical development.
Again, we are very honored and excited to have Dr. Kaixian Chen as a valuable addition to the CBA team. We look forward to working with Dr. Chen to take CBA to a higher level in the future.
CBA-USA Successfully Held the Fourth Biopharmaceutical Development Workshop on February 19, 2017 in Maryland, USA
2016-2017 Workshop series-4
Entrepreneurs in Biopharmaceutical field
Sharing experience and advising your real start-up plan
CBA-USA successfully organized the fourth seminar of biopharmaceutical development workshop on February 19, 2017. This event is co-sponsored by Chinese Culture and Community Service Center (CCACC), Chinese Students and Scholars Association at the National Institute of Health (NIH-CSSA) and American Society for Quality-Washington DC and Maryland Metro, Section 509. Nearly 80 professionals attended the forth work shop at CCACC in Gaithersburg, Maryland.
CBA currently has over 3000 registered individual members (www.cba-USA.org).The goal of this series of CBA workshops is to provide opportunities for biomedical professionals to gain a deeper understanding of drug development and marketing approval. At the same time, the CBA workshop is a unique networking platform for local biomedical professionals. Speakers and attendees will have opportunities to discuss the current state-of-art practice, future directions, and career development in biopharmaceutical field.
The forth workshop focused on how to successfully start, run and grow your biopharmaceutical companies. We invited four entrepreneurs from biopharmaceutical industry, ranging from small start-ups to multinational biotech and contract research organization (CRO). The speakers presented their distinguished backgrounds and past achievements, as well as successful and failed stories during entrepreneurship. Further, valuable advice and guidance were shared for future entrepreneurs. Markedly, family support is critical for running a successful business.
Dr. Dazhi Lai, founder of SPEED Biosystems, started his reagent service company after being frustrated as a postdoctoral researcher in Yale University and the NIH. He mentioned that entrepreneurship not only gives him financial reward, but also promotes his spirituality. Next, Mr. Charles Li, senior director of Poochon Scientific LLC, presented their sophisticated business model of how to identify customers, expand market and practically analyze profit. The third speaker is previous CBA president Patrick Y. Lu. Currently, he is founder, president and CEO of Sirnaomics, Inc.in Rockville, Maryland and chairman of board of directors of Suzhou Sirnaomics Pharmaceuticals, Ltd. in Biobay, SIP, China. Dr. Lu showed his impressive 20 years’ drug discovery and development trip to potentially the first RNAi based therapy, which could be used for treatment of many diseases. At the same time, Dr. Lu has published many top-class research articles and applied for many patents. The last speaker Dr. Dan Zhang is chairman of board of directors of Fountain Medical Development. He also served as CBA president previously. Dr. Zhang shared his unique experience in working with both governments and venture capitals in China. His company is one of the largest CROs in China. Dr. Zhang shared his insight into current biopharmaceutical industry in China. During lunch and network time, participants had good communications with each other. At the end of the workshop, Drs. Frank Li and George Chang hosted the panel discussion and lottery.
CBA is dedicated to bridging the Chinese and US biopharmaceutical industries. We will continue to organize the bimonthly workshop. CBA will organize career development workshop and job fair in April. The 2017 CBA annual conference will be in June. We will post more information in the following month. Please stay tuned. If you have any advice for this event, please feel free to contactcontact@cba-usa.org.
注册后，你将收到确认的电子邮件，还会告诉你参会的具体信息。After registering, you will receive a confirmation email containing information about joining the meeting.
讲座内容： 1. 新冠病毒的药物研发与公众科普
Yebin Zhou, Ph.D. Dr. Zhou was trained as a geneticist and immunologist at University of Alabama at Birmingham. He completed his postdoc training in autoimmune research at MedImmune, AstraZenecca. Since then, Dr. Zhou has joined AbbVie as a senior scientist in Immuno-Oncology. In his spare time, Dr. Zhou also enjoyed writing popular science online.
2. Remdesivir临床试验的解析及新冠肺炎疫情应对的探讨
Angela Zeng, M.D., Ph.D., Vice president of CBA, Clinical Study Physician in Ascentage Pharma. Dr. Zeng is a well-trained surgeon and medical scientist. She has near 20 years’ experience in clinical medicine and currently serves as a study physician leading global clinical trials for early development of new drugs.
3. 中美新冠病毒临床试验之比较
Dan Zhang, MD, MPH, the Executive Chairman of Fountain Medical Development (FMD), a clinical CRO with 1700 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia & USA. He also served as General Secretary of “Thousands of Talents Program”.Before founding FMD in 2007, Dr. Zhang was the Head of Clinical Development and Head of Safety Assessment at Sigma-Tau Research Inc., a leading Italian Pharmaceutical Company. Prior to that, he was the Vice President at the Quintiles Transnational Corp., the world largest clinical CRO, and Chairman of Quintiles Medical Development (Shanghai) Company Ltd.
2020初始，新型肺炎疫情的进展速度超出了大家的预期。位于美国首都华盛顿的美国华人生物医药科技协会（CBA），本计划在大年初一举行一年一度的庆祝中国新年的盛装酒会。考虑到在大华府地区久负盛名的CBA Chinese New Year Gala规模大（近200人聚会），层次高（嘉宾包括联邦，州，郡和驻美使馆的官员和议员，各大公司主管以及著名艺术家），专业强（成员都是生物医药方面的专家），我们果断取消了这次酒会。这样的果断决定得到了全体嘉宾的由衷支持和感谢！
在疫情肆虐的非常时期，为了尽快地得到控制，美国FDA会有一套变通的做法，包括允许使用一些还没有被FDA批准的药物，或者用在还没有被批准的适应症上。但FDA的具体规定如何呢？CBA第二十三任会长，美国BLA Regulatory公司的李利博士加班加点，果断地把FDA的Emergency Use Authorization (EUA)法规翻译成中文，并无偿提供给国内的制药企业和政府机关参考和借鉴。该法规的中文文本可以联系CBA免费索取。
